NCT05876689 is a clinical trial of DREAM OCT in Eye Diseases, sponsored by Robert T. Chang, MD.

Who is sponsoring NCT05876689?

NCT05876689 is sponsored by Robert T. Chang, MD.

What drugs are being tested in NCT05876689?

Interventions in NCT05876689: DREAM OCT.

What condition does NCT05876689 study?

NCT05876689 studies Eye Diseases, Myopia, Glaucoma.

Is NCT05876689 still recruiting?

NCT05876689 is currently completed. Last updated 25 November 2024.

Last reviewed 2024-11-25 · How we verify

NCT05876689

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Swept Source OCT Imaging With the DREAM VG-OCT

Completed Last updated 25 November 2024

What this trial tests

trial testing DREAM OCT in Eye Diseases in 154 participants. Completed in 1 October 2024.

Timeline

9 October 2023

Primary endpoint
1 October 2024

1 October 2024

Quick facts

Lead sponsor	Robert T. Chang, MD
Status	Completed
Study type	OBSERVATIONAL
Enrollment	154
Start date	9 October 2023
Primary completion	1 October 2024
Estimated completion	1 October 2024
Sites	1 location across United States

Drugs / interventions tested

DREAM OCT

Conditions studied

Eye Diseases — all drugs for Eye Diseases →
Myopia — all drugs for Myopia →
Glaucoma — all drugs for Glaucoma →

Sponsor

Robert T. Chang, MD

Who can join

18 and older, any sex, with Eye Diseases or Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Intalight Dream OCT is the first combo anterior plus posterior device to perform both OCT and OCT-A at depth of 16mm. This is especially useful in patient who are very nearsighted as it allows us to image all in one frame. The intention of this study is to see how the images differ on the same patients when compared to the Cirrus OCT and to test for the repeatability of the images on a single day.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Eye Diseases

Currently open trials in the same condition.

NCT07322302 — RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs) · NA · recruiting
NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
NCT06812845 — Patterns of Eye Diseases Among Patients Attending The Eye Investigation Unit of Sohag University Hospital · recruiting
NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05876689 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Robert T. Chang, MD
Last refreshed: 25 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05876689.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing